Amitabh Goswami
Interventional Pain Medicine · Fresno, CANPI 1447451539
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 75.7% of it on its own, with 50 other manufacturers making up the rest. Among interventional pain medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,294 payments — averaging $77.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$76K
- Painteq LLC$9K
- Spinal Simplicity, LLC$3K
- Relievant Medsystems, Inc.$2K
- Nalu Medical, Inc.$2K
- Abbott$2K
- plus $6K from 45 others
Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$16
Across 5 payments — averaging $29,895 each. An ownership or investment interest held by the physician or an immediate family member.
- Spinal Simplicity, LLC$149K
What the payments were for
- Consulting fees$13,41913%
- Speaking & faculty fees$45,68345%
- Travel & lodging$5,2975%
- Food & beverage$34,61234%
- Education$1,8022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CROSSBOSS$15,649
- GENERAL PAIN MANAGEMENT$7,541
- SPECTRA WAVEWRITER$6,941
- WAVEWRITER ALPHA$6,750
- GENERAL - THERAPIES$6,369
- WaveWriter Alpha Prime 16$6,292
- Intracept$3,742
- HA MINUTEMAN G3-R$2,461
- PAINTEQ$2,056
- Nalu Neurostimulation System$902
- PROCLAIM$453
- INFINION$379
- Infinion 16$253
- LINEAR$245
- AJOVY$238
- FIXATE$232
- ETERNA$205
- Vyrsa V1$132
- ENTRADA$117
- Superion ISS$113
How this compares
$100,812 in reported general payments places this provider in the 90th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 13 | $24,687 |
| HorizantGabapentin Enacarbil | 21 | $15,018 |
| BelbucaBuprenorphine Hcl | 12 | $11,840 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 320 | $4,520 |
| ZtlidoLidocaine | 12 | $4,375 |
| Lidocaine | 70 | $3,987 |
| Gabapentin | 468 | $3,651 |
| Duloxetine Hcl | 131 | $1,729 |
| Clonidine | 14 | $1,290 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $1,167 |
| Celecoxib | 29 | $838 |
| Pregabalin | 23 | $594 |
| Oxycodone Hcl | 20 | $487 |
| Tramadol Hcl | 96 | $378 |
| Cyclobenzaprine Hcl | 30 | $330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Belbuca | $84 | $36,52625 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $139 | $15,01821 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $327 | $4,37512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in Fresno
- Gregory SmithFresno$92K
- Paul KyFresno$30K
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.